# Senda Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/senda-biosciences

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.sendabiosciences.com
- Total disclosed funding: $192M
- Latest round: Series C (Apr 18, 2022)
- Investors on record: 12

## About

Founded in 2017 and based in Massachusetts, US, Senda Biosciences, Inc. operates as a biotechnology company that creates novel treatments for human disease. The company was co-founded by David Kolesky, David Berry, and Ignacio Martinez. In June 2021, Senda Biosciences raised USD 98 million in Series B funding from Flagship Pioneering, Longevity Vision Fund, Terra Magnum Capital Partners, Mayo Clinic, Partners Investment, and Mint Venture Partners.

Senda Biosciences is a company that is harnessing the molecular interactions that have evolved over millennia between humans, plants, and bacteria to develop new types of medicines. The company offers its Intersystems Biology that focuses on molecular connections between botanical, bacterial, and human cells—coevolved over millennia—define health and disease. It builds research on the microbiome, omics, and big data, and traditional taxonomic descriptions to delineate interspecies interactions using techniques in machine learning and computational biology. The company's discovery platform identifies, quantifies, and locates molecular connections with hundreds of times the diversity of traditional stool-based sampling methods.

The company plans to develop its platform and therapeutic programs into clinical trials.

## Funding rounds

- Series C, Apr 18, 2022, $72M — Flagship Pioneering, Michigan Department of Treasury, Alexandria Venture Investments, Stage 1 Ventures, Qatar Investment Authority, Samsung Venture Investment, Mayo Clinic, Partners Investment, Longevity Vision Holding, Bluwave Capital LLC
- Series B, Jun 10, 2021, $98M — Flagship Pioneering, Michigan Department of Treasury, Alexandria Venture Investments, Mayo Clinic, Partners Investment, Terra Magnum Capital Partners, Longevity Vision Holding, Mint Venture Partners
- Series A, Oct 28, 2020, $22M — Flagship Pioneering

## Investors

- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series A, Series B, Series C
- Michigan Department of Treasury — Series B, Series C
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B, Series C
- Mayo Clinic — Series B, Series C
- Partners Investment (https://capitalatlas.ai/funds/partners-investment) — Series B, Series C
- Terra Magnum Capital Partners (https://capitalatlas.ai/funds/terra-magnum-capital-partners) — Series B
- Longevity Vision Holding (https://capitalatlas.ai/funds/longevity-vision-holding) — Series B, Series C
- Mint Venture Partners (https://capitalatlas.ai/funds/mint-venture-partners) — Series B
- Stage 1 Ventures (https://capitalatlas.ai/funds/stage-1-ventures) — Series C
- Qatar Investment Authority (https://capitalatlas.ai/funds/qatar-investment-authority) — Series C
- Samsung Venture Investment (https://capitalatlas.ai/funds/samsung-venture-investment) — Series C
- Bluwave Capital LLC (https://capitalatlas.ai/funds/bluwave-capital-llc) — Series C